Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 72 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M1HhPWN6fG:2b4jpZ{BCe3OjeR?= NWfzTXFqOTBibl2= NHTHZ5M4OiCq NXfUOIVrTE2VTx?= NEDXc5FRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MmP6NlQ6ODB6N{O=
HT-29 NXzGSJBrS3m2b4TvfIlkKEG|c3H5 NXPK[mJzOTBibl2= MkXoO|IhcA>? MofWSG1UVw>? M33hUXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MVKyOFkxODh5Mx?=
HT-29 M4rKO2N6fG:2b4jpZ{BCe3OjeR?= MWixNEBvVQ>? MWi3NkBp MXTEUXNQ MWTQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> MoPkNlQ6ODB6N{O=
PC3 MlXFT4lv[XOnIFHzd4F6 NWfLW3JpOTByIH7N MmfXNUBp NIOwOnJFVVOR NH3XUWhRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> MWmyNVk4QDZ6Mx?=
PC3 M{nzWWtqdmG|ZTDBd5NigQ>? NW\kSVZ2OTByIH7N NYrCbnZmOSCq NWS1RmFMTE2VTx?= MXPEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MViyNVk4QDZ6Mx?=
PC3 M2rWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3sS5MyNjVizszN Mk\tNUBp NHTw[oZFVVOR NUjvT5hRUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N MlTxNlE6Pzh4OEO=
HEK293 M2H3PWZ2dmO2aX;uJGF{e2G7 NGnXeFMyODBibl2= NGT5b2U5KGh? M2LIO2ROW09? MWnJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? MVOyNVU{QTNyMR?=
BT-20 NHPpVYVMcW6jc3WgRZN{[Xl? M{LiUVIxKM7:TR?= MorKSG1UVw>? NYXZSGNxTG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= M33kWlIyOzV|NUWx
U937 Mn\KRY51cWKjY4TldolidCCDc4PhfS=> M3XTXVUxKM7:TR?= NIDD[4U1QCCq MVXEUXNQ M2DyTmlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NVHVTmZzOjFzNEKxNFY>
U937 MlfqRY51cWKjY4TldolidCCDc4PhfS=> M{HORlUxKM7:TR?= MYC0PEBp MVvEUXNQ MnuxSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NInxNYgzOTF2MkGwOi=>
U937 NIG3cpdCdnSrYnHjeIVzcWGuIFHzd4F6 M3;LWFUxKM7:TR?= MoHtOFghcA>? NXLGXlM2TE2VTx?= NEnLUGNFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? MV2yNVE1OjFyNh?=
MCF-7 MlXHRZV1d3CqYXf5JGF{e2G7 NGLSV4w{OCCwTR?= MXG0JIg> NWjhPVlrTE2VTx?= MU\JcoR2[2W|IHH1eI9xcGGpeR?= NI\BR5gzODB{OEGzOC=>
U87MG NI\IWGhMcW6jc3WgRZN{[Xl? MlLUNUDPxE1? MWi2JIg> M4jDVGROW09? MVHQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? NVjXVlJiOTl6NEi0NFQ>
U87MG NVLhUYwxU2mwYYPlJGF{e2G7 MkD3NUDPxE1? NWLrVXZLPiCq MlXoSG1UVw>? M3HLd3BwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MoK3NVk5PDh2MES=
U87MG MnzXT4lv[XOnIFHzd4F6 MkjLNUDPxE1? MojCOkBp NGjuVGlFVVOR MXXEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MYWxPVg1QDRyNB?=
U87MG NWTXZodlU2mwYYPlJGF{e2G7 NVLKWGtCOSEQvF2= M3\YWlYhcA>? NEG3NYlFVVOR NYHxS2l{TG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w M1T0cFE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb MoCzRZV1d3CqYXf5JGF{e2G7 M{LoNVAvOiEQvF2= MUSyOEBp MorNSG1UVw>? M4n0Umlv\HWlZYOgZZV1d3CqYXf5 NWq0b29DOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 MYTBeZRweGijZ4mgRZN{[Xl? NUXROFdbOC5{IN88US=> MmfpNlQhcA>? M17EXGROW09? NEKwUYNKdmS3Y3XzJIF2fG:yaHHnfS=> NV\4fFBVOTh|OUG5OFk>
H4 MYDGeY5kfGmxbjDBd5NigQ>? MUCwMlIh|ryP NGfCT5gzPCCq NUC0ZnpMTE2VTx?= MUTJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz M3fnNVE5ODJ2NUi0
HeLa MXPGeY5kfGmxbjDBd5NigQ>? Mn36NVAxKG6P NX\PfWZUOzZiaB?= NWnOe|ZrTE2VTx?= NXG5d2FuUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NH\ofYsyPzV4M{O4OS=>
HeLa M3LhTmZ2dmO2aX;uJGF{e2G7 NVnXUIw6OTByIH7N NHrwUnY{PiCq M2T4W2ROW09? NH;tRVJKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? NF;HcZcyPzV4M{O4OS=>
HeLa NG\X[mpHfW6ldHnvckBCe3OjeR?= M{nYPVExOCCwTR?= M1;W[lM3KGh? NYrDNVBsTE2VTx?= M2fkeWlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> MUCxO|U3OzN6NR?=
SYF Mn;mSpVv[3Srb36gRZN{[Xl? NIWyVmoyODBibl2= MUCyOEBp MUXEUXNQ M3;qb2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> MVGxO|U3OzN6NR?=
SYF MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS0ZoNCOTByIH7N NYHFXZZEOjRiaB?= MXLEUXNQ NHTyWoFKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NXfvcXFLOTd3NkOzPFU>
HEK293T MmraRY51cX[rcnHsJGF{e2G7 NGPZZ5UyKG6P NXHRTo5GPCCm MVfEUXNQ MlraTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NUPze3pKOTd2OEW1NFE>
HEK293T NWPJRmtrSW62aY\pdoFtKEG|c3H5 NX3tOoZKOSCwTR?= NVHhd|hyPCCm NXjTNmVVTE2VTx?= M{jTZmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N M3S4U|E4PDh3NUCx
PBMC MUPGeY5kfGmxbjDBd5NigQ>? NFrJSZUyKG6P MYqxOEBl NH\Be2lFVVOR NHjBfXRT\WS3Y3XzJGNEWjViZHXud4l1gQ>? MoHaNVc1QDV3MEG=
PBMC Mo\oSpVv[3Srb36gRZN{[Xl? M1fWUVEhdk1? NWe5T2ZqOTRiZB?= M{LINGROW09? MYnEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NYjPO29VOTd2OEW1NFE>
HEK293 cells NGm4Wm9McW6jc3WgRZN{[Xl? NUjEOmg1PTBibl2= NYDqeXNEPDVibXnu MnKxSG1UVw>? NIT5WZlKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P MV2xO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc Ml;HSpVv[3Srb36gRZN{[Xl? NFjvc5AyODBibl2= NXjD[W5kPCCq M2myZ2ROW09? M{e2WGlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk MmjQNVcyOjh{NkK=
Human mixed lymphocyte MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX61JI5O MWHEUXNQ Mnn5TWM2OD1zLk[gcm0v MonrNVYyQDV6NkW=
Lewis rat lymph node cells M4ntVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK1JO69VQ>? MUnEUXNQ MlHjTWM2OD1{Lk[g{txO NWe5VZBDOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj1NVAhdk1? M1LoOlczKGh? MUHEUXNQ NYH0O2JTUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> Mn;aNVAxOjF7NEi=
MRK-nu-1 M3fDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXYWYNKSzVyPUCuPFQ2KHCP MojHV2FPT0WU
OCUB-M NEGxeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVwMkSgdG0> M3rKOHNCVkeHUh?=
SF539 NXzWeopYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFzLk[gdG0> MnHoV2FPT0WU
ES4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq4TWM2OD1{MT61JJBO MmDoV2FPT0WU
RL95-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFyNzDwUS=> NGWyNY1USU6JRWK=
LC-2-ad NUjoPIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTZWnpxUUN3ME20NlMheE1? NIfuZpdUSU6JRWK=
Daudi M3L0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZNWlEPTB;NEO0JJBO M1T6UnNCVkeHUh?=
NTERA-S-cl-D1 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HlV2lEPTB;NESzJJBO M1zSUHNCVkeHUh?=
OS-RC-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;xToxYUUN3ME22OVIheE1? Mki5V2FPT0WU
VA-ES-BJ NUHlSolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDO2lEPTB;N{KzJJBO M4PzdnNCVkeHUh?=
GR-ST NV;nTItiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvpTWM2OD16NE[gdG0> NVPrcWljW0GQR1XS
SW872 NFL0dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP5TWM2OD16NE[gdG0> NWO5RYJsW0GQR1XS
NOS-1 NVvEV2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTh5MTDwUS=> NET4ZnNUSU6JRWK=
MC116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTl6NTDwUS=> MmDOV2FPT0WU
NCI-H1355 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwMEGgcm0> NYfFSItPW0GQR1XS
RPMI-8226 NVvVfmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMUmgcm0> M2HFdnNCVkeHUh?=
TE-15 NHOxO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XsVWlEPTB;MT6zOkBvVQ>? NFrMUXhUSU6JRWK=
Ramos-2G6-4C10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwNE[gcm0> MYPTRW5ITVJ?
KU812 M{XvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljWTWM2OD1{LkCxJI5O MWfTRW5ITVJ?
EW-1 NU\Kd2llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5RWlnUUN3ME2yMlE4KG6P M{TYUHNCVkeHUh?=
KS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HpSWlEPTB;Mj60OUBvVQ>? MoHRV2FPT0WU
SK-LMS-1 M{\rUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nURWlEPTB;Mj60PUBvVQ>? M4jVTXNCVkeHUh?=
TGBC1TKB NF6wRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXkR21OUUN3ME2yMlY6KG6P MWLTRW5ITVJ?
TE-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6eXZKSzVyPUKuO|chdk1? NFLPUVFUSU6JRWK=
ETK-1 NHHGfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KTWM2OD1{LkiyJI5O NUHpbHJ4W0GQR1XS
BE-13 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LINGlEPTB;Mj65PUBvVQ>? MXjTRW5ITVJ?
A3-KAW MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjiTWM2OD1{Lkm5JI5O NX3DeYJlW0GQR1XS
TE-10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThZ2lEPTB;Mz6zJI5O MmniV2FPT0WU
DOHH-2 M{G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2eWlEPTB;Mz6zOUBvVQ>? M4\uW3NCVkeHUh?=
ES6 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3qTZZMUUN3ME2zMlQ{KG6P MU\TRW5ITVJ?
OPM-2 NGq4OYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXETWM2OD12LkG1JI5O M3e3dHNCVkeHUh?=
SH-4 NYmz[21KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ubmlEPTB;ND6zOEBvVQ>? NFPLdmVUSU6JRWK=
NB13 M{Pt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GzO2lEPTB;ND6zOkBvVQ>? NYHsSItLW0GQR1XS
HUTU-80 NEXhTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILOd|FKSzVyPUSuOFIhdk1? MXzTRW5ITVJ?
CCRF-CEM MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK0cJZmUUN3ME20Mlk1KG6P MlfQV2FPT0WU
TGBC24TKB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTVwNUGgcm0> NVjmOYV[W0GQR1XS
697 M1z5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jScmlEPTB;Nj6yPEBvVQ>? NUH0XpR7W0GQR1XS
J-RT3-T3-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzPZVRKSzVyPU[uOFYhdk1? M3vVTnNCVkeHUh?=
KALS-1 NX;LXmpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\mOpN1UUN3ME22MlU3KG6P NFniNmRUSU6JRWK=
no-10 M2nibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkezTWM2OD15LkK5JI5O NXLCSHMxW0GQR1XS
SK-NEP-1 M3jkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLqTWM2OD16Lke5JI5O M360enNCVkeHUh?=
L-540 NUmyToRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPEOoFmUUN3ME2xNE41OiCwTR?= Ml3pV2FPT0WU
JiyoyeP-2003 NHToZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5dGlEPTB;MUCuPVQhdk1? MXzTRW5ITVJ?
HH MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDWXJNKSzVyPUGxMlM6KG6P M1zVdHNCVkeHUh?=
SR M{XvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljOTWM2OD1zMT60OUBvVQ>? Mlf3V2FPT0WU
QIMR-WIL NIrTVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCxTWM2OD1zMT64OUBvVQ>? MnLPV2FPT0WU
A4-Fuk MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC5XXVKSzVyPUGzMlEzKG6P MUHTRW5ITVJ?
CESS MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLZWXJDUUN3ME2xN{4yOyCwTR?= MYfTRW5ITVJ?
KE-37 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PsVGlEPTB;MU[uNFchdk1? MX3TRW5ITVJ?
SK-UT-1 M3HVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF4LkixJI5O M{PJeHNCVkeHUh?=
SIG-M5 M{jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF5LkK1JI5O MV7TRW5ITVJ?
HT NWjWdY44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOcFBKSzVyPUG3MlYhdk1? NEHLdHBUSU6JRWK=
DEL NY\OXpI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkS29VUUN3ME2xO{46QSCwTR?= MULTRW5ITVJ?
SK-PN-DW MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXDTWM2OD1{MD6yN{BvVQ>? MVrTRW5ITVJ?
RPMI-8402 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJzLke3JI5O NVzNOZY6W0GQR1XS
RPMI-6666 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ2LkSyJI5O NGTvc3RUSU6JRWK=
NCI-H720 M{\Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXpTWM2OD1{NT60NUBvVQ>? MX\TRW5ITVJ?
EW-16 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTsWopKSzVyPUK2Mlg4KG6P NXyxS45wW0GQR1XS
BL-70 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnpTWM2OD1{OD6zPEBvVQ>? MmLkV2FPT0WU
SF126 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfZTWM2OD1|MD6zPEBvVQ>? MXvTRW5ITVJ?
BC-1 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHviToxKSzVyPUOxMlI3KG6P MkXsV2FPT0WU
MHH-PREB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN{LkS0JI5O NUTIPXFSW0GQR1XS
A101D MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[wSGlEPTB;M{KuOlIhdk1? MnXGV2FPT0WU
NMC-G1 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;IXXMxUUN3ME2zN{43PyCwTR?= MnTmV2FPT0WU
LB1047-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr5WIJKSzVyPUO0MlY6KG6P M1rDOHNCVkeHUh?=
EM-2 M17Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN6LkWzJI5O M3raUnNCVkeHUh?=
COLO-684 M3nzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN7Lkigcm0> MVnTRW5ITVJ?
Becker NWTUVpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRzLkC1JI5O M1\2UnNCVkeHUh?=
BL-41 M4TXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL5OGMyUUN3ME20N{43PiCwTR?= NVSySW1nW0GQR1XS
MDA-MB-134-VI NXj0b3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L1c2lEPTB;NESuNFIhdk1? M3rhWHNCVkeHUh?=
L-363 NES1bYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTR2LkezJI5O MVvTRW5ITVJ?
ECC4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPEWZZKSzVyPUS0Mlc5KG6P M4\jfXNCVkeHUh?=
A388 M1fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFUWFMUUN3ME20OE45OiCwTR?= M4TzbHNCVkeHUh?=
HEL NWnqbJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLlOJVDUUN3ME20PU44QSCwTR?= M1K1S3NCVkeHUh?=
RKO NVPpWI14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLGXINKSzVyPUWwMlI6KG6P MX;TRW5ITVJ?
KINGS-1 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTVzLkW1JI5O MoPSV2FPT0WU
EB-3 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTNcHN7UUN3ME21Nk43PyCwTR?= M2\OV3NCVkeHUh?=
ARH-77 NYHyeVE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[w[ZVKSzVyPUWyMlghdk1? NH[0OWtUSU6JRWK=
GCIY MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3Wem1KSzVyPUWzMlQ3KG6P NH7OZZdUSU6JRWK=
NCI-H1304 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTV5LkKyJI5O M1rLV3NCVkeHUh?=
KARPAS-299 M2foVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonpTWM2OD14MT64NkBvVQ>? NGnxXHJUSU6JRWK=
IA-LM NI\kSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexdndKSzVyPU[4MlE{KG6P NYrmUmRIW0GQR1XS
GI-1 M33SOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HR|hkUUN3ME23NE4{QSCwTR?= M1vsOHNCVkeHUh?=
TE-11 M{e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\nRmlEPTB;N{euNVchdk1? MVzTRW5ITVJ?
LS-411N MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn0UXpKSzVyPUe3MlU4KG6P MY\TRW5ITVJ?
no-11 M1XrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn3SmVKSzVyPUizMlI1KG6P MmPnV2FPT0WU
MV-4-11 NXLySG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTPTHJ4UUN3ME24N{44OyCwTR?= NXj5[ZdWW0GQR1XS
BV-173 M1vCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTh|Lkm3JI5O M{LKSHNCVkeHUh?=
CMK MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTrTWM2OD16ND6xOkBvVQ>? NX7BdlEzW0GQR1XS
LC4-1 NXT3Z3ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL1T2E2UUN3ME24Ok44OiCwTR?= M{LHXnNCVkeHUh?=
COR-L279 M1XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCO2lEPTB;OEeuNlUhdk1? M2SwcnNCVkeHUh?=
NCI-H209 NGLPT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD16Nz60NUBvVQ>? Mor4V2FPT0WU
Raji NInKdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK0S|JnUUN3ME24PU44OiCwTR?= M2DrOHNCVkeHUh?=
LB996-RCC M3q1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT0ZnZSUUN3ME25N{41OyCwTR?= Mke5V2FPT0WU
NCI-H526 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfr[Y1KSzVyPUmzMlU6KG6P M{XS[nNCVkeHUh?=
KGN NULtXIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rNVmlEPTB;OU[uNlkhdk1? NEjhXHJUSU6JRWK=
MOLT-4 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2UXJKSzVyPUm2Mlc6KG6P MnnnV2FPT0WU
PF-382 NX\MToVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4OHZYUUN3ME25Ok44QSCwTR?= NXHp[2FkW0GQR1XS
BC-3 NF7CenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq2TWM2OD17OT6xPEBvVQ>? NYD0OZJsW0GQR1XS
KARPAS-422 M1HDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFyMj6wPUBvVQ>? MYPTRW5ITVJ?
SBC-1 M1LCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDLelNKSzVyPUGwO{44PSCwTR?= NF\pUnRUSU6JRWK=
LC-1F MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlb|ltUUN3ME2xNFgvODVibl2= MWrTRW5ITVJ?
GB-1 M{O5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP2TWM2OD1zMEmuNFIhdk1? MXPTRW5ITVJ?
SNB75 NGD6fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHYTGdQUUN3ME2xNVkvPjlibl2= NWLqfmw6W0GQR1XS
BB65-RCC MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzOT65N{BvVQ>? MVzTRW5ITVJ?
NCI-N87 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\jTWM2OD1zMkGuPVghdk1? M1rGbHNCVkeHUh?=
IST-MEL1 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{Mj6zPEBvVQ>? NFr6ZpZUSU6JRWK=
HOP-62 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHCdItKSzVyPUGyOk45QSCwTR?= MXPTRW5ITVJ?
ACN NU\JZ45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF2Nj63OUBvVQ>? MlvLV2FPT0WU
DMS-114 M3;zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezUlZUUUN3ME2xOVAvPjdibl2= MmHlV2FPT0WU
MLMA M1f4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpcGlEPTB;MUW5Mlg5KG6P NWn5[oRsW0GQR1XS
HT-144 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPxd3FIUUN3ME2xOlUvPDNibl2= M{DSc3NCVkeHUh?=
C2BBe1 NWXsfHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3STWM2OD1zNkeuO|Yhdk1? NX7xUWtmW0GQR1XS
L-428 NUj1XmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILGT25KSzVyPUG3O{44KG6P M2jlc3NCVkeHUh?=
DU-4475 NYHJ[FA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\YTWM2OD1zOEeuOlghdk1? M3H3OnNCVkeHUh?=
CP67-MEL M13mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rUbWlEPTB;MUm5MlM5KG6P NX3hOohVW0GQR1XS
MEG-01 M4rqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnpNo1KSzVyPUKwNU46PiCwTR?= MnK3V2FPT0WU
IST-SL2 NHn1PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELBWHBKSzVyPUKwPE43OyCwTR?= NFGyTVdUSU6JRWK=
ES8 NVnmNG9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjGcGNKSzVyPUKyOU46PCCwTR?= MnPZV2FPT0WU
COLO-800 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qwT2lEPTB;MkO1MlI5KG6P Mlr2V2FPT0WU
MFH-ino M1f0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjONY1FUUN3ME2yN|UvQDRibl2= MkHwV2FPT0WU
OVCAR-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XVWlEPTB;MkO3MlI1KG6P NIfEUnpUSU6JRWK=
PSN1 M3TyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ2Mj63NUBvVQ>? MYrTRW5ITVJ?
EW-12 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCTWM2OD1{NEOuNUBvVQ>? MoLrV2FPT0WU
HCC1599 NV3vVYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ4MT60O{BvVQ>? NIPa[3FUSU6JRWK=
SJSA-1 M1fuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXUTWM2OD1{N{GuOFYhdk1? M2nUeXNCVkeHUh?=
ST486 M3jMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS4TWM2OD1{OU[uNVQhdk1? Ml\OV2FPT0WU
NOMO-1 M1vFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNyMD6yNUBvVQ>? MXLTRW5ITVJ?
MN-60 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\wTWM2OD1|MEWuN|Ihdk1? NIi3dZRUSU6JRWK=
HCC1187 NGrwZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXPSmlKSzVyPUOwO{4zPSCwTR?= NGLIeJZUSU6JRWK=
SW982 NXTnT|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv3W2FKSzVyPUOxOE44PSCwTR?= Mm[4V2FPT0WU
LB647-SCLC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKSWlEPTB;M{K4MlcyKG6P M3HLeXNCVkeHUh?=
HC-1 M4PyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN|NT61JI5O MYnTRW5ITVJ?
EHEB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnPdWhSUUN3ME2zN|cvPTJibl2= M12xenNCVkeHUh?=
TUR M2TGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\rTWM2OD1|NkOuPVUhdk1? NIDPcFJUSU6JRWK=
LU-139 NY\lR286T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN5OD6wNkBvVQ>? NYrmV5hCW0GQR1XS
NB1 NIH6Z|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:4TWM2OD1|OESuOFUhdk1? MY\TRW5ITVJ?
BB30-HNC M{nPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3kfWVPUUN3ME2zPFgvOzJibl2= M{DxWHNCVkeHUh?=
HAL-01 NUXn[GV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTWUm57UUN3ME2zPFkvOjZibl2= M2nyfHNCVkeHUh?=
K5 NInWTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkUYVKSzVyPUSxNU4{PyCwTR?= M17lWXNCVkeHUh?=
MZ2-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP2TWM2OD12MUOuOlQhdk1? Ml:2V2FPT0WU
RXF393 NHLLTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKyNlNKSzVyPUSxOk41PSCwTR?= Mn\EV2FPT0WU
NCI-H1648 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXvcWdKSzVyPUSxO{42OyCwTR?= M1TlPHNCVkeHUh?=
TE-12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHkcm94UUN3ME20N|QvOjZibl2= M2\ETXNCVkeHUh?=
EoL-1- M4nxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDpTXJ[UUN3ME20N|cvQThibl2= M2q3U3NCVkeHUh?=
JAR NXrOenFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTESYp2UUN3ME20N|gvPjJibl2= M3X4eXNCVkeHUh?=
DSH1 M2PkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\ac|ZKUUN3ME20OVgvQTFibl2= NWrtVWR6W0GQR1XS
NCI-H187 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGexN2lKSzVyPUS2Nk45OSCwTR?= Mn;0V2FPT0WU
HCE-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnJTWM2OD12N{euOlYhdk1? NHW4V4lUSU6JRWK=
8-MG-BA NEnVdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHFTWM2OD13OEGuOVIhdk1? NInR[VNUSU6JRWK=
KLE NH\YZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTV6NT6yJI5O M2nqbnNCVkeHUh?=
KNS-42 NGXvXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jM[WlEPTB;NUi2MlgyKG6P NXfvZZd4W0GQR1XS
MSTO-211H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fqPWlEPTB;NkC5Mlc1KG6P NIC0S3lUSU6JRWK=
GDM-1 NVPrR3poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZzND6wPUBvVQ>? NILsRXpUSU6JRWK=
TE-1 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETRXmRKSzVyPU[0Ok4yOiCwTR?= MWXTRW5ITVJ?
BT-474 M37Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZ2Nz6wOkBvVQ>? MYXTRW5ITVJ?
KARPAS-45 NF24[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfuTWM2OD14NEeuOkBvVQ>? M1Xk[nNCVkeHUh?=
MOLT-16 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnxZodXUUN3ME22OFcvQTNibl2= NWC5fFZmW0GQR1XS
KURAMOCHI NGnPdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHGTJlmUUN3ME22OVcvPTFibl2= NX3Re29RW0GQR1XS
K-562 M2\pUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDqcopYUUN3ME22OlkvPTFibl2= NXnRXIVqW0GQR1XS
EKVX Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZ5Mj63NUBvVQ>? NWWxOFVRW0GQR1XS
GAK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvBUZdKSzVyPU[3OU4{KG6P MlLuV2FPT0WU
NCI-SNU-5 M{LiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj0VIJKSzVyPU[5NE4xOSCwTR?= NH:5fo5USU6JRWK=
NCI-H2126 NXm5[mdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTESVhqUUN3ME23NlYvQDdibl2= NWm2NVNNW0GQR1XS
CTV-1 NWOzc2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjvS2NKSzVyPUe0OE46KG6P M1i1WHNCVkeHUh?=
SW962 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HKZ2lEPTB;N{S4MlQ1KG6P M3zYb3NCVkeHUh?=
MONO-MAC-6 NFrFR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnftTWM2OD15NU[uPVMhdk1? NHjHOYNUSU6JRWK=
NCI-H748 M1vtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLxc2RKSzVyPUe1PE46QSCwTR?= MoP6V2FPT0WU
NCI-H524 M3WxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXVTWM2OD15OECuO|Mhdk1? NVzwXllRW0GQR1XS
LS-123 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPTWM2OD15OUWuOlkhdk1? M3;KVXNCVkeHUh?=
NB7 M1vhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHIWZZZUUN3ME24NVQvOTRibl2= MlftV2FPT0WU
LS-1034 M1PGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ToeGlEPTB;OEK4Mlk5KG6P MlPOV2FPT0WU
TE-5 NUD6UHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXyTWM2OD16OEOuOVYhdk1? NX;FVXRwW0GQR1XS
A704 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTh7OT6xOUBvVQ>? NXi0XmpiW0GQR1XS
TK10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfwTWM2OD17MU[uNFMhdk1? NYXZOVVJW0GQR1XS
NCI-H345 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T4PWlEPTB;OUSzMlIzKG6P Ml21V2FPT0WU
CGTH-W-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fLXmlEPTB;OUS4MlE{KG6P NF3pXYRUSU6JRWK=
NCI-H510A NILYToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37YNGlEPTB;OUi1MlEzKG6P NWS1RWJXW0GQR1XS
NCI-H1963 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HxUWlEPTB;MT6wN|I6OiEQvF2= NWO1OFdXW0GQR1XS
SCC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[xTWM2OD1zLkCzOFE1KM7:TR?= NVfyO3RFW0GQR1XS
EW-11 M1TOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4TppIUUN3ME2xMlA5PzR|IN88US=> NXPueHdXW0GQR1XS
CPC-N MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zxRmlEPTB;MT6wPFgh|ryP NEfpdFFUSU6JRWK=
NCI-H1417 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jSbmlEPTB;MT6xNlI3KM7:TR?= MVrTRW5ITVJ?
DG-75 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXxVlZKSzVyPUGuNVYzQDVizszN NID6N2RUSU6JRWK=
HD-MY-Z M1fkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrXTWM2OD1zLkG2OFE3KM7:TR?= NVzQWlFIW0GQR1XS
ATN-1 NVrwW4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvQU49KSzVyPUGuNlYzODlizszN NEm4Z3lUSU6JRWK=
KM-H2 NEPsT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDSTWM2OD1zLkK2OFA5KM7:TR?= MWDTRW5ITVJ?
NCI-H2081 NXXVcJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwMk[2N|ch|ryP NIjnNZVUSU6JRWK=
HL-60 NFjQe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5c4FKSzVyPUGuNlY6PTlizszN MknSV2FPT0WU
DB M362[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn6TWM2OD1zLkK3NlQzKM7:TR?= Ml;0V2FPT0WU
NCI-H1522 M4K3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7qPIpWUUN3ME2xMlI5QDh5IN88US=> NUXhVJcxW0GQR1XS
AM-38 NVT0VlhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwM{C3NkDPxE1? MXfTRW5ITVJ?
NCI-H446 NUT3NYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX0WIlKSzVyPUGuN|IyOjFizszN NH3KfZpUSU6JRWK=
SU-DHL-1 NWqy[YV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOyTWM2OD1zLkOyPFAyKM7:TR?= NF7NT4pUSU6JRWK=
NH-12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXa[JZKSzVyPUGuN|Y{PzRizszN MoTZV2FPT0WU
DMS-79 NWHKRpBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H4dmlEPTB;MT6zOlg3PiEQvF2= Mo\0V2FPT0WU
NCI-H716 NWnGcYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX25O|U1UUN3ME2xMlM5QTh4IN88US=> M4O1ZXNCVkeHUh?=
ML-2 M3qzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvdYVKSzVyPUGuOFE2OjlizszN M3rueXNCVkeHUh?=
NB10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXKRm5KSzVyPUGuOFY3OzJizszN NYXoPVR4W0GQR1XS
ONS-76 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3CWXVKSzVyPUGuOVM2PjlizszN M2LLSXNCVkeHUh?=
LOUCY M33aVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwNUS2OVch|ryP NFHUVJpUSU6JRWK=
SCLC-21H M2fjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjKTWM2OD1zLkW4OVgzKM7:TR?= NUm5NINqW0GQR1XS
TGW M3X4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M122SWlEPTB;MT62N|k4PSEQvF2= NI\QU3hUSU6JRWK=
LXF-289 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj5TWM2OD1zLkezNlY5KM7:TR?= NEexdm9USU6JRWK=
BB49-HNC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fvOmlEPTB;MT63N|U5PiEQvF2= M3z2SnNCVkeHUh?=
NCI-H747 NH;DU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzobXE6UUN3ME2xMlc2OzR4IN88US=> M4XWfnNCVkeHUh?=
LU-165 NIX4dXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi1T4dJUUN3ME2xMlg1QTh4IN88US=> M1:2b3NCVkeHUh?=
OMC-1 NXezT5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwOUWwOlYh|ryP MVTTRW5ITVJ?
RCC10RGB Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfRSmN2UUN3ME2xMlk2QDF5IN88US=> MoS0V2FPT0WU
SW684 NYT3d4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwOU[wPVkh|ryP MXrTRW5ITVJ?
TE-8 M3fofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmcZdKSzVyPUKuNFU2PTlizszN MmK2V2FPT0WU
SK-N-DZ M2LoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fLUmlEPTB;Mj6xN|I4PCEQvF2= NXHGcZpZW0GQR1XS
EVSA-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K0VWlEPTB;Mj6xO|MyPSEQvF2= NX\VbIpPW0GQR1XS
KASUMI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwMUi4NVUh|ryP MXLTRW5ITVJ?
NKM-1 M4PjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLwN5VDUUN3ME2yMlI2PDd{IN88US=> MVPTRW5ITVJ?
CAL-148 M1\xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS0[YJKSzVyPUKuN|M3OTRizszN NH7mdpZUSU6JRWK=
NCI-H64 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwM{SyN|Ih|ryP M4DLfHNCVkeHUh?=
KNS-81-FD MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjXOXRKSzVyPUKuN|Y3OiEQvF2= MVvTRW5ITVJ?
KM12 NWLsc5JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZS3JKSzVyPUKuOFA5OzlizszN NVjKO2k5W0GQR1XS
SW954 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrTTWM2OD1{LkS3O|c6KM7:TR?= NWS2OoFpW0GQR1XS
NCI-H1395 NWS3WZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrQdIc6UUN3ME2yMlUzPjR3IN88US=> NG\3W2hUSU6JRWK=
DJM-1 NYrUfFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vmeGlEPTB;Mj62NFY{KM7:TR?= MVvTRW5ITVJ?
COLO-668 NILBT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXXUJJmUUN3ME2yMlgzPjl3IN88US=> NV7mPVhMW0GQR1XS
NCI-H1436 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnUelBKSzVyPUKuPFU3OTVizszN NUTue3c2W0GQR1XS
LB2241-RCC M3;E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTOeXZKSzVyPUKuPFY5OzlizszN MU\TRW5ITVJ?
GT3TKB NWm2[49OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUfXp{UUN3ME2yMlg6ODV3IN88US=> NU\VTZVPW0GQR1XS
COLO-824 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLXTWM2OD1{Lki5O|Y5KM7:TR?= M17Gd3NCVkeHUh?=
ES1 NV65Z3RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi3bmVKSzVyPUKuPFk5PzlizszN NGLURmlUSU6JRWK=
LB771-HNC NYnDcYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPWU5FKSzVyPUKuPVA6PDZizszN MlzKV2FPT0WU
GI-ME-N NFfC[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHtTWM2OD1|LkCwPVA1KM7:TR?= NEDTS2JUSU6JRWK=
NALM-6 NXP2PJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwMEC5N|Mh|ryP NG\vc4xUSU6JRWK=
LU-134-A NIO3c2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfaOWxwUUN3ME2zMlA2PDJ3IN88US=> Mn75V2FPT0WU
DMS-153 NYXNZVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDVZXdKSzVyPUOuNFU5OjRizszN NG\zfHRUSU6JRWK=
MZ1-PC M2Xke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HBT2lEPTB;Mz6wPVA4QCEQvF2= NHvO[4NUSU6JRWK=
NCI-H1155 NX\QdnB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDwZXhFUUN3ME2zMlEyPjFizszN MkD4V2FPT0WU
CAS-1 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH0TWM2OD1|LkGzO|A4KM7:TR?= MmHZV2FPT0WU
D-502MG M3XHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SxUmlEPTB;Mz6xOFM6KM7:TR?= NFSxZYZUSU6JRWK=
NCI-H2141 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTNwMUe0OVIh|ryP MYTTRW5ITVJ?
NB6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7SVINKSzVyPUOuNVgzPTlizszN M13XPHNCVkeHUh?=
NCCIT MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nle2lEPTB;Mz6yNVgxQSEQvF2= MX3TRW5ITVJ?
NB69 NWTPO|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwM{G4PVEh|ryP NIPa[lhUSU6JRWK=
JVM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fHcGlEPTB;Mz6zOlQ{OyEQvF2= NW[wO|hOW0GQR1XS
K052 NEjKbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwM{e5Olgh|ryP MofRV2FPT0WU
HCC2157 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETjfZVKSzVyPUOuOVMzOjhizszN NHXRS5FUSU6JRWK=
KMOE-2 NU\PcGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNwNUSyOFIh|ryP MYDTRW5ITVJ?
SF268 NH7LdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ezPGlEPTB;Mz63NVU2PCEQvF2= MkL3V2FPT0WU
CHP-126 NUPUUFk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu1S|BKSzVyPUOuO|Y1PThizszN NWW5O|k5W0GQR1XS
CP66-MEL NVjWZ5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXLSXhVUUN3ME2zMlc6ODl2IN88US=> NFnBWZBUSU6JRWK=
NCI-H69 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvBTWM2OD12LkCxPVM3KM7:TR?= M4npPHNCVkeHUh?=
A253 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HyTmlEPTB;ND6wNlExOSEQvF2= M1fDPHNCVkeHUh?=
NB14 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwMUC0O|kh|ryP MlGwV2FPT0WU
NCI-H1694 NIPJSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG3WlhnUUN3ME20MlE{OTF{IN88US=> NYK2T5ZTW0GQR1XS
NCI-H2196 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DlR2lEPTB;ND6xO|E3QSEQvF2= Mkn5V2FPT0WU
TE-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKxcW9GUUN3ME20MlE4PTh{IN88US=> MoP2V2FPT0WU
D-283MED NYXFdog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDiPXdyUUN3ME20MlE5QDRizszN M1zKXXNCVkeHUh?=
OCI-AML2 M2DHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwMUm0PFkh|ryP MUTTRW5ITVJ?
D-263MG MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\YNGlEPTB;ND6yNlk3OSEQvF2= NIjnOohUSU6JRWK=
MPP-89 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjsTWM2OD12LkK3N|A1KM7:TR?= NHrmZ3VUSU6JRWK=
LAMA-84 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTHd2d[UUN3ME20MlMxPDJzIN88US=> M3;OfHNCVkeHUh?=
LB373-MEL-D NWm2eopVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrrVlFoUUN3ME20MlM3Pzh7IN88US=> MXPTRW5ITVJ?
UACC-257 NInYeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXja[ZI3UUN3ME20MlM6PTN2IN88US=> NFHYUG1USU6JRWK=
MC-CAR NYTHT29uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Px[GlEPTB;ND60N|k6KM7:TR?= MmLVV2FPT0WU
COLO-320-HSR M1yzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xbmlEPTB;ND60OFQzPyEQvF2= MUTTRW5ITVJ?
P30-OHK NX\KcZVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTRwNk[1PFEh|ryP MV\TRW5ITVJ?
UACC-812 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\sO2lEPTB;ND62PVE3OSEQvF2= NXTDZ3JjW0GQR1XS
CTB-1 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwN{G1OVUh|ryP MYXTRW5ITVJ?
ALL-PO Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LYWmlEPTB;ND64OFA4PyEQvF2= NHPHVndUSU6JRWK=
SK-MEL-2 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvTWM2OD12Lki2PVU2KM7:TR?= M1HsSXNCVkeHUh?=
TC-YIK NY\VZnM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\kTWM2OD12Lkm3PVQzKM7:TR?= MUfTRW5ITVJ?
NCI-H1882 M1jWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorqTWM2OD13LkCyNFAyKM7:TR?= NIi3WGVUSU6JRWK=
MHH-CALL-2 M{HkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDwcFJUUUN3ME21MlA2ODR{IN88US=> MXXTRW5ITVJ?
U-87-MG NU\jNZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwMEm0OlYh|ryP MoPTV2FPT0WU
NCI-H1092 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:4U4dkUUN3ME21MlI3PTV3IN88US=> NEC4WFFUSU6JRWK=
TE-441-T NETaepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TQNWlEPTB;NT6yO|gzKM7:TR?= M{K4THNCVkeHUh?=
SK-MEL-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLtTpJKSzVyPUWuNlkxPDRizszN M3rqbHNCVkeHUh?=
EW-22 NVTXSGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrUdVBKSzVyPUWuNlk1PjZizszN MnzHV2FPT0WU
MZ7-mel NFzRdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHRTWM2OD13LkSwOlkyKM7:TR?= NYjrWnVoW0GQR1XS
LP-1 M{nGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwNEGyPVEh|ryP NInxSoVUSU6JRWK=
NCI-SNU-16 NHXTPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwNkSwO|Qh|ryP MlG3V2FPT0WU
LU-65 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDiTWM2OD13Lke2N|c{KM7:TR?= M4HYbHNCVkeHUh?=
CW-2 NVf3dpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrxTWM2OD13Lki1PVU6KM7:TR?= M3HNd3NCVkeHUh?=
WSU-NHL NWfOXHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGzd|FqUUN3ME21Mlk2OTd2IN88US=> M4rDXHNCVkeHUh?=
IST-MES1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTVwOUW0OFMh|ryP MWjTRW5ITVJ?
U-266 NELtOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTVwOUiyNFIh|ryP NYLmdphsW0GQR1XS
TALL-1 NHjjbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwMUS2PFgh|ryP NIm1UpNUSU6JRWK=
Calu-6 NHj0O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\qN|BIUUN3ME22MlE2OzF4IN88US=> NUjMe2hPW0GQR1XS
MMAC-SF NVPIWZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4dGlEPTB;Nj6xPFU2PiEQvF2= M1HzPHNCVkeHUh?=
NCI-H82 NXHDUYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG1TWM2OD14LkKwOFg6KM7:TR?= NGOwVJlUSU6JRWK=
RS4-11 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnsOYtPUUN3ME22MlI2QDl5IN88US=> MmjBV2FPT0WU
SNU-C2B NFOxdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG3W2FKSzVyPU[uOFA6PjlizszN MnPTV2FPT0WU
BOKU NX\lZ5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jiZ2lEPTB;Nj60O|U6PyEQvF2= NFmzVZNUSU6JRWK=
C8166 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jtUWlEPTB;Nj61OVkyOiEQvF2= M4jNT3NCVkeHUh?=
D-247MG MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTdwMESzOFch|ryP NX6xTWVjW0GQR1XS
EW-18 M1rZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwMEeyPVIh|ryP MkHGV2FPT0WU
KG-1 NGjyXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq0TWM2OD15Lk[yO|M5KM7:TR?= MWHTRW5ITVJ?
REH NWrSXJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD15Lk[4NVA6KM7:TR?= MVHTRW5ITVJ?
U-698-M MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTdwOESzNVUh|ryP NYDyRYJjW0GQR1XS
KP-N-RT-BM-1 NWDxSIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\FTWM2OD15LkmzNFI6KM7:TR?= Ml3lV2FPT0WU
MS-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PqXGlEPTB;Nz65OlA1OSEQvF2= M3;aOnNCVkeHUh?=
SNU-C1 NXzMXXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:yb5hKSzVyPUeuPVgyQTJizszN NGG5ZmFUSU6JRWK=
SK-MM-2 NH33UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;DWGRKSzVyPUiuNlYxPjVizszN M3\4dHNCVkeHUh?=
LAN-6 MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJW2poUUN3ME24MlMxODBzIN88US=> NV\uNnZbW0GQR1XS
NEC8 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwM{C2PVEh|ryP Ml;VV2FPT0WU
NCI-H1770 NGDBdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jVcWlEPTB;OD6zPFAxOiEQvF2= MUnTRW5ITVJ?
D-336MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjUVnNKSzVyPUiuOFAyOTZizszN MWDTRW5ITVJ?
COLO-829 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThwNEi4O|kh|ryP M3;RWHNCVkeHUh?=
LS-513 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDvTWM2OD16LkW5OVk6KM7:TR?= NWnCd|JoW0GQR1XS
YT NFq0XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO1TFdKSzVyPUiuOlI1OjdizszN MXTTRW5ITVJ?
EW-24 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD16Lke2OVQh|ryP NGXtZWFUSU6JRWK=
IST-SL1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDJTWM2OD16Lki2OVQ{KM7:TR?= M2\jdHNCVkeHUh?=
CA46 M3O3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDmR4NYUUN3ME24Mlk2ODl6IN88US=> NUHrV4dMW0GQR1XS
NCI-H1838 M2H5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nTWlEPTB;OD65PFYxOiEQvF2= Ml\UV2FPT0WU
NCI-H719 NELtbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzPTWM2OD17LkK1Nlc6KM7:TR?= NV36XItwW0GQR1XS
HCE-T MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHZTWM2OD17LkOwPFUyKM7:TR?= NXzI[nNXW0GQR1XS
A498 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH60[4dKSzVyPUmuN|YyOjRizszN MlPMV2FPT0WU
LB831-BLC NXj5OHhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT0PYZZUUN3ME25Mlc3PTJzIN88US=> NGPTbI1USU6JRWK=
SKM-1 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD17Lki1PVY{KM7:TR?= MnPNV2FPT0WU
THP-1 MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WzcWlEPTB;OT65OlkyQCEQvF2= Mn\tV2FPT0WU
SHP-77 M3Kx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWOGlEPTB;MUCuOFA4KM7:TR?= M4f0NnNCVkeHUh?=
EW-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD1zMD62Nlg6KM7:TR?= MVXTRW5ITVJ?
KY821 M37EfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFyLke2N{DPxE1? MnLhV2FPT0WU
NCI-SNU-1 NGH4N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTLTWM2OD1zMT6wNlE4KM7:TR?= NHPmeVhUSU6JRWK=
HCC2218 M2XFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFzLkO5PFYh|ryP NGDsNGhUSU6JRWK=
IM-9 M3rkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe4RpdKSzVyPUGxMlUyODZizszN MX;TRW5ITVJ?
NCI-H889 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD1zMT61N|E{KM7:TR?= MlLyV2FPT0WU
HDLM-2 NYLjbJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF{LkSxOVkh|ryP MmPvV2FPT0WU
LB2518-MEL NH76O3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrUTIFmUUN3ME2xNk43QDF3IN88US=> MVXTRW5ITVJ?
NCI-H23 NV7L[W1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF|LkK0NlUh|ryP NX3hV|FwW0GQR1XS
NB17 NXLZS3IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGTZNOUUN3ME2xN{41PTd7IN88US=> NUe2PGk{W0GQR1XS
NCI-H322M NHXlSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXOTWM2OD1zND60NFY5KM7:TR?= MkToV2FPT0WU
SUP-T1 NXzMUWdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvxSZRKUUN3ME2xOE41OTNizszN M2LXcHNCVkeHUh?=
ES3 M2HrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLwW3dKUUN3ME2xOU4xPzB|IN88US=> M{WxOnNCVkeHUh?=
ES5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TVTmlEPTB;MUWuNFc5PyEQvF2= M1L0N3NCVkeHUh?=
NCI-H1650 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\UbGlEPTB;MUWuOFk4QSEQvF2= M{m1UXNCVkeHUh?=
NCI-H226 NGTuXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIezem5KSzVyPUG1Mlg4PjhizszN MXvTRW5ITVJ?
COR-L88 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv4SY9KSzVyPUG2MlMyPCEQvF2= NHnRRnNUSU6JRWK=
SCC-15 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\NUZdKSzVyPUG2MlM5PjlizszN MWfTRW5ITVJ?
GOTO MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF4LkS3PVMh|ryP NHzE[XVUSU6JRWK=
SIMA MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nXO2lEPTB;MU[uOFgxOiEQvF2= MXvTRW5ITVJ?
NCI-H1299 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzZ5RKSzVyPUG3MlE2QTFizszN NF[5bGFUSU6JRWK=
NCI-H1581 M{\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX1TWM2OD1zNz60NlE6KM7:TR?= MV;TRW5ITVJ?
MHH-NB-11 M2ftXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DKPGlEPTB;MUeuPVY5OyEQvF2= NYHaNoQyW0GQR1XS
MFM-223 M{jMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz3TWM2OD1zOD6wOVM5KM7:TR?= M{nWTXNCVkeHUh?=
ES7 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrEd3pKSzVyPUG4MlU1OzFizszN MofBV2FPT0WU
JVM-3 NU\adnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nkbGlEPTB;MUiuO|E4KM7:TR?= MXjTRW5ITVJ?
RL M3vHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXpUGVKSzVyPUKwMlM5QCEQvF2= MVTTRW5ITVJ?
EC-GI-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XoR2lEPTB;MkGuNlA1OSEQvF2= NGnOenFUSU6JRWK=
LNCaP-Clone-FGC NIr0NlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG2b|JKSzVyPUKxMlY4PjhizszN NGf2dHZUSU6JRWK=
IMR-5 NVfrdHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLki0PVQh|ryP MU\TRW5ITVJ?
KP-N-YS NUnZOmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLseXlNUUN3ME2yNU45PzVizszN M2HBSHNCVkeHUh?=
Mo-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rkZmlEPTB;MkKuNlE5PSEQvF2= MkXMV2FPT0WU
NCI-H128 NFvXWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ|LkW4OVMh|ryP NGW1[WtUSU6JRWK=
RH-1 M13yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L1dGlEPTB;MkOuO|g3PiEQvF2= MlH4V2FPT0WU
NCI-H2171 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLwTWM2OD1{ND6yOFg2KM7:TR?= MWfTRW5ITVJ?
RPMI-8866 NXTIN|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnPbXpoUUN3ME2yOk44PDJizszN M1rSWHNCVkeHUh?=
SK-N-FI Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nc2tKSzVyPUK3MlM5OTFizszN M2LydnNCVkeHUh?=
LOXIMVI M3fXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fnNGlEPTB;MkeuPFA2OSEQvF2= MUTTRW5ITVJ?
P31-FUJ MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5c4dKSzVyPUOxMlU{PzRizszN M1vDZnNCVkeHUh?=
KMS-12-PE NWnsWWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXyRW1JUUN3ME20PU42OzB{IN88US=> MVzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1
NCT03298958 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio December 1 2018 Phase 3
NCT03433183 Not yet recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca December 2018 Phase 2
NCT03721614 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. December 1 2018 Not Applicable
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID